Abiopharma

🔍 Collard Craig A (Executive)

Company: HERON THERAPEUTICS, INC. /DE/ (HRTX)

Report Date: 2026-04-03

Detailed Transactions and Holdings:

• Acquired 62,500 shares of Common Stock (Direct)
  Date: 2026-04-03 | Code: M | equity_swap_involved: false | shares_owned_after: 648,255.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 62,500 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-03 | Code: M | equity_swap_involved: false | shares_owned_after: 62,500.00 | transaction_form_type: 4 | Footnotes: F3, F3

Footnotes:

• F1: Each restricted stock unit represents a contingent right to receive one share of common stock.
• F2: Includes 14,045 shares acquired under the Heron Therapeutics, Inc. 1997 Employee Stock Purchase Plan on April 30, 2025.
• F3: The restricted stock units vest in four equal annual installments beginning one year after the date of grant, subject to the Reporting Person's continued service to the Issuer through the vesting date.